Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting ...

Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J., Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

In July, The Princeton, New Jersey-based company announced an interim update on the open-label, investigator-initiated study ...

This year's award marks 30 years since clinicians first used ECP to successfully treat chronic graft versus host disease (cGvHD).1 In recognition of this important milestone, this year's $75,000 grant ...

Follicular lymphoma is the most common type, but others include marginal zone, cutaneous T-cell and lymphoplasmacytic ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...

SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 CTCL Trial to Initiate Before End of 2024 Soligenix, Inc.

The following is a summary of “Integrative epidemiology and immuno-transcriptomics uncover a risk and potential mechanism for ...

Most common types of cancer that can look like eczema are squamous cell skin cancer and basal cell skin cancer ...